GNSZ On July 12th Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in HCC patients, presented the HCC clinical trial update for G-202, in Taipei, Taiwan.
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!